Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems

Bibliography

• PREVENTION PROGRAM: Expert panel report 2: guidelines for the diagnosis and management of asthma. (1997).
   Google Scholar
• HARTERT TV, PEEBLES RS Jr: Epidemiology of asthma: the year in review. Curr. Opin. Pulm. Med. (2000) 6:4–9.
   Google Scholar
• BUSSE WW, LEMANSKE RS Jr: Asthma. N Engl. J. Med. (2001) 344:350–362.
   Google Scholar
• BUSSE WW, ROSENWASSER LJ: Mechanisms of asthma. J. Allergy Clin. Immunol (2003) 111:S799–S804.
   Google Scholar
• RODRIGO GJ, RODRIGO C, HALL JB: Acute asthma in adults. Chest (2004) 125:1081–1102.
   Google Scholar
• WEISS GB, GERGEN PJ, HODGSON TA: An economic evaluation of asthma in the United States. N Engl. J. Med. (1992) 326:862–866.
   Google Scholar
• SMITH DH, MALONE DC, LAWSON KA et al.: A national estimate ofthe economic costs of asthma. Am. J. Respir. Crit. Care Med. (1997) 156:787–793.
   Google Scholar
• BUHL R: Budesonide/formoterol for the treatment of asthma. Expert Opin. Pharmacother. (2003) 4:1393–1406.
   Google Scholar
• VIGNOLA AM: Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting 02-agonists on asthma pathophysiology: a review of the evidence. Drugs (2003) 63:35–51.
   Google Scholar
• WILLIAMS DM: Clinical considerations in the use of inhaled corticosteroids in asthma. Pharmacotherapy (2001) 21:38S–48S.
   Google Scholar
• JUNIPER EF, KLINE PA, VANZIELEGHEM MA et al.: Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur. Respir. J. (1990) 3:1122–1127.
   Google Scholar
• JUNIPER EF, KLINE PA, VANZIELEGHEM MA et al.: Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Rev. Respir. Dis. (1990) 142:832–836.
   Google Scholar
• LEVY ML, STEVENSON C, MASLEN T: Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax (1996) 51:1087–1092.
   Google Scholar
• BARNES PJ: Efficacy of inhaled corticosteroids in asthma. J. Allergy Clin. Immunol (1998) 102: 531–538.
   Google Scholar
• ••A review describing the clinical efficacy ofinhaled corticosteroids.
   Google Scholar
• KANNIESS F, RICHTER K, BOHME S, JORRES RA, MAGNUSSEN H: Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. EurRespir. J. (2002) 20:853–858.
   Google Scholar
• KELLY HW: Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann. Allergy Asthma Immunol (2003) 91:326–334.
   Google Scholar
• DOLOVICH MB: Physical principles underlying aerosol therapy. J. Aerosol Med. (1989) 2:171–185.
   Google Scholar
• NEWMAN SP: Deposition and effects of inhaled corticosteroids. Clin. Pharmacokinet. (2003) 42:529–544.
   Google Scholar
• ISSAR M, MOBLEY C, KHAN P, HOCHHAUS G: Pharmacokinetics and pharmacodynamics of drugs delivered to the lungs. In: Pharmaceutical Inhalation Aerosol Technology. AJ Hickey (Ed.), Marcel Dekker, Inc., New York, NY, USA (2004) 215–252.
   Google Scholar
• HOCHHAUS G, DERENDORF H, TALTON J, MOLLMAN H: Factors Involved in the pulmonary targeting of inhaled glucocorticoids: the use of pharmcokinetic/dynamic simulations. In: Inhaled Steroids in Asthma: Optimizing Effects in the Airways. RP S PM O' SJ S R Brattsand (Eds), Marcel Dekker, Inc., New York, NY, USA (2002) 283–308.
   Google Scholar
• HOCHHAUS G, MOLLMANN H, DERENDORF H, GONZALEZ-ROTHI RJ: Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model./ Clin. Pharmacol (1997) 37:881–892.
   Google Scholar
• •Description of the PlUPD model used for simulations performed in this article.
   Google Scholar
• BEATO M, KALIMI M, FEIGELSON P: Correlation between glucocorticoid binding to specific liver cytosol receptors and enzyme induction in vivo. Biochem. Biophys. Res. Commun. (1972) 47:1464–1472.
   Google Scholar
• DAHLBERG E, THALEN A, BRATTSAND R et al.: Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 a, 17a-acetal-substituted glucocorticoids. MoL Pharmacol (1984) 25:70–78.
   Google Scholar
• DRUZGALA P, HOCHHAUS G, BODOR N: Soft drugs-10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J. Steroid Biochem. Mol Biol. (1991) 38:149–154.
   Google Scholar
• HOCHHAUS G, MOLLMANN H: Pharmacokinetic/pharmacodynamic characteristics of the 0-2-agonists terbutaline, salbutamol and fenoterol. Int. J. Clin. Pharmacol. Ther. Toxicol (1992) 30:342–362.
   Google Scholar
• HOCHHAUS G, MOELLMANN H: B-Agonists: terbutaline, albuterol, and fenoterol. In: Handbook of Pharmacokinetic/ Pharmacodynamic Correlation. H D G Hochhaus (Eds), CRC, New York, NY, USA (1995) 299–322.
   Google Scholar
• VAYSSIERE BM, DUPONT S, CHOQUART A et al.: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol. EndocrinoL (1997) 11: 1245–1255.
   Google Scholar
• ADCOCK IM, NASUHARA Y, STEVENS DA, BARNES PJ: Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-x13 and lack of I-x13 involvement. Br. J. Pharmacol (1999) 127: 1003–1011.
   Google Scholar
• ISSAR M, SAHASRANAMAN S, HOCHHAUS G: Differences in selectivity of inhaled glucocorticoids to the glucocorticoid receptor. Annual Meeting of the American Academy of AllerD Asthma, and Immunology. San Francisco, CA, USA (2004).
   Google Scholar
• DERENDORF H: Pharmacokinetic andpharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med. (1997) 91:22–28.
   Google Scholar
• RYRFELDT A, ANDERSSON P, EDSBACKER S et al.: Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. j Respir. Dis. Suppl (1982) 122:86–95.
   Google Scholar
• DERENDORF H, HOCHHAUS G, ROHATAGI S et al.: Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration./ Clin. Pharmacol (1995) 35:302–305.
   Google Scholar
• DALEY-YATES PT, PRICE AC, SISSON JR, PEREIRA A, DALLOW N: Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br. J. Clin. Pharmacol (2001) 51:400–409.
   Google Scholar
• DICKENS G, WERMELING D, MATHENEY C et al.: Flunisolide administered via metered dose inhaler with and without spacer and following oral administration./ Allergy Clin. Immunol. (1999) 103:S132.
   Google Scholar
• HOCHHAUS G, CHEN LS, RATKA A et al.: Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J. Pharm. Sci. (1992) 81:1210–1215.
   Google Scholar
• TABURET AM, SCHMIT B: Pharmacokinetic optimization of asthma treatment. Clin. Pharmacokinet. (1994) 26:396–418.
   Google Scholar
• PROCOPIOU PA, BIGGADIKE K, ENGLISH AF et al.: Novel glucocorticoid antedrugs possessing a 17beta-(gamma-lactone) ring. J. Med. Chem. (2001) 44:602–612.
   Google Scholar
• BRAIN JD, VALBERG PA: Deposition of aerosol in the respiratory tract. Am. Rev. Respir. Dis. (1973) 120: 1325–1373.
   Google Scholar
• MORROW PE: Aerosol characterization and deposition. Am. Rev. Respir. Dis. (1974) 110:88–99.
   Google Scholar
• PRITCHARD JN: The influence of lung deposition on clinical response. J. Aerosol Med. (2001) 14:S19–S26.
   Google Scholar
• DHAND R: Aerosol therapy for asthma. Curr. Opin. Pulm. Med. (2000) 6:59–70.
   Google Scholar
• DOLOVICH MB: Practical aspects of imaging techniques employed to study aerosol deposition and clearance. In: Pharmaceutical Inhalation Aerosol Technology AJ Hickey (Ed.), Marcel Dekker, Inc., New York, NY, USA (2004) 171–214. A review on the imaging techniques used to characterise lung deposition.
   Google Scholar
• NEWMAN SP, WILDING IR: Imaging techniques for assessing drug delivery in man. Pharm. Sci. Technol Today (1999) 2:181–189.
   Google Scholar
• NEWMAN SP, BROWN J, STEED KP, READER SJ, KLADDERS H: Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest (1998) 113:957–963.
   Google Scholar
• LABRIS NR, DOLOVICH MB: Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. (2003) 56:600–612.
   Google Scholar
• TOOGOOD JH: An appraisal of the influence of dose frequency on the antiasthmatic activity of inhaled corticosteroids. Ann. Allergy (1985) 55:2–4.
   Google Scholar
• SUAREZ S, GONZALEZ-ROTHI RJ, SCHREIER H, HOCHHAUS G: Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm. Res. (1998) 15:461–465.
   Google Scholar
• SHEK PN, SUNTRES ZE, BROOKS JI: Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery. J. Drug Target (1994) 2:431–442.
   Google Scholar
• FIELDING RM, ABRA RM: Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm. Res. (1992) 9:220–223.
   Google Scholar
• EDWARDS DA, HANES J, CAPONETTI G et al.: Large porous particles for pulmonary drug delivery. Science (1997) 276: 1868–1871.
   Google Scholar
• DELLAMARY LA, TARARA TE, SMITH DJ et al.: Hollow porous particles in metered dose inhalers. Pharm. Res. (2000) 17:168–174.
   Google Scholar
• BOT AI, TARARA TE, SMITH DJ et al.:Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. (2000) 17:275–283.
   Google Scholar
• GREEN SA, SPASOFF AP, COLEMAN RA, JOHNSON M, LIGGETT SB: Sustained activation of a G protein-coupled receptor via 'anchored' agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J. Biol. Chem. (1996) 271:24029–24035.
   Google Scholar
• WIESLANDER E, DELANDER EL, JARKELID Let al.: Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro. Am. J. Respir. Cell Md. Biol. (1998) 19:477–484.
   Google Scholar
• MILLER-LARSSON A, MATTSSON H, HJERTBERG E et al.: Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab. Dispos. (1998) 26:623–630.
   Google Scholar
• TUNEK A, SJODIN K, HALLSTROM G:Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab. Dispos. (1997) 25:1311–1317.
   Google Scholar
• NELSON HS, CHAPMAN KR, PYKE SD, JOHNSON M, PRITCHARD JN: Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J. Allergy Clin. Immunol (2003) 112:29–36.
   Google Scholar